Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Myriad Genetics (MYGN) FCF Margin (2016 - 2025)

Historic FCF Margin for Myriad Genetics (MYGN) over the last 17 years, with Q3 2025 value amounting to 8.9%.

  • Myriad Genetics' FCF Margin rose 102100.0% to 8.9% in Q3 2025 from the same period last year, while for Sep 2025 it was 2.02%, marking a year-over-year increase of 95600.0%. This contributed to the annual value of 3.31% for FY2024, which is 198100.0% up from last year.
  • As of Q3 2025, Myriad Genetics' FCF Margin stood at 8.9%, which was up 102100.0% from 7.7% recorded in Q2 2025.
  • Myriad Genetics' FCF Margin's 5-year high stood at 37.38% during Q1 2021, with a 5-year trough of 32.91% in Q4 2023.
  • Moreover, its 5-year median value for FCF Margin was 11.03% (2025), whereas its average is 10.8%.
  • As far as peak fluctuations go, Myriad Genetics' FCF Margin tumbled by -694000bps in 2022, and later soared by 343300bps in 2024.
  • Over the past 5 years, Myriad Genetics' FCF Margin (Quarter) stood at 8.02% in 2021, then crashed by -54bps to 12.32% in 2022, then tumbled by -167bps to 32.91% in 2023, then soared by 104bps to 1.42% in 2024, then skyrocketed by 525bps to 8.9% in 2025.
  • Its FCF Margin was 8.9% in Q3 2025, compared to 7.7% in Q2 2025 and 11.03% in Q1 2025.